EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial

Diego A S Toesca, William F Hartsell, Todd A DeWees, John H Chang, Brady S Laughlin, Molly M Voss, Christopher A Dodoo, Nasiruddin Mohammed, Sameer R Keole, Lisa A McGee, Vinai Gondi, Patrick J Sweeney und 5 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2024.05.014 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Diego A S Toesca und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona. Hauptthemen laut MEDLINE: Dose Fractionation, Radiation, Prostate-Specific Antigen, Prostatic Neoplasms, Proton Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We aimed to determine if ultrahypofractionated proton therapy delivered via stereotactic body proton therapy (SBPT) is noninferior to conventionally fractionated proton therapy (CFPT) in patients with early prostate cancer. METHODS AND MATERIALS: This study was a multicenter, randomized, controlled, noninferiority phase 3 trial that included patients with histologically confirmed low-risk prostate adenocarcinoma defined by Gleason score grouping 1, Prostate-specific antigen

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose Fractionation, RadiationProstate-Specific AntigenProstatic NeoplasmsProton TherapyQuality of LifeRadiosurgeryAgedAged, 80 and overHumansMaleMiddle Aged

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
  • Proton Collaborative Group, Warrenville, Illinois; Radiation Oncology Consultants, Elk Grove Village, Illinois.
  • Division of Biostatistics, City of Hope, Duarte, California.
  • University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
  • Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
  • Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, Illinois.

Zitieren

APA

Toesca, D. A. S., Hartsell, W. F., DeWees, T. A., Chang, J. H., Laughlin, B. S., Voss, M. M., Dodoo, C. A., Mohammed, N., Keole, S. R., McGee, L. A., Gondi, V., Sweeney, P. J., Dorn, P., Sinesi, C. C., Doh, L. S., Rich, T., & Vargas, C. E. (2024). Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.05.014

Vancouver

Toesca DAS, Hartsell WF, DeWees TA, Chang JH, Laughlin BS, Voss MM, et al. Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.05.014

BibTeX
@article{Toesca2024,
  author = {Toesca, Diego A S and Hartsell, William F and DeWees, Todd A and Chang, John H and Laughlin, Brady S and Voss, Molly M and Dodoo, Christopher A and Mohammed, Nasiruddin and Keole, Sameer R and McGee, Lisa A and Gondi, Vinai and Sweeney, Patrick J and Dorn, Paige and Sinesi, Christopher C and Doh, Lucius S and Rich, Tyvin and Vargas, Carlos E},
  title = {Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2024.05.014}
}
Kostenlos starten →